GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Yumanity Therapeutics Inc (FRA:8IY) » Definitions » EV-to-FCF

Yumanity Therapeutics (FRA:8IY) EV-to-FCF : -0.49 (As of May. 22, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Yumanity Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Yumanity Therapeutics's Enterprise Value is €11.53 Mil. Yumanity Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2022 was €-23.63 Mil. Therefore, Yumanity Therapeutics's EV-to-FCF for today is -0.49.

The historical rank and industry rank for Yumanity Therapeutics's EV-to-FCF or its related term are showing as below:

FRA:8IY's EV-to-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 9.49
* Ranked among companies with meaningful EV-to-FCF only.

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-22), Yumanity Therapeutics's stock price is €1.47. Yumanity Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was €-2.750. Therefore, Yumanity Therapeutics's PE Ratio for today is At Loss.


Yumanity Therapeutics EV-to-FCF Historical Data

The historical data trend for Yumanity Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yumanity Therapeutics EV-to-FCF Chart

Yumanity Therapeutics Annual Data
Trend Dec19 Dec20 Dec21
EV-to-FCF
-0.82 -6.78 -0.46

Yumanity Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.74 -0.46 -0.28 -0.30 -0.34

Competitive Comparison of Yumanity Therapeutics's EV-to-FCF

For the Biotechnology subindustry, Yumanity Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yumanity Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Yumanity Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Yumanity Therapeutics's EV-to-FCF falls into.



Yumanity Therapeutics EV-to-FCF Calculation

Yumanity Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=11.527/-23.63
=-0.49

Yumanity Therapeutics's current Enterprise Value is €11.53 Mil.
Yumanity Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-23.63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Yumanity Therapeutics  (FRA:8IY) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Yumanity Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.47/-2.750
=At Loss

Yumanity Therapeutics's share price for today is €1.47.
Yumanity Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.750.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Yumanity Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Yumanity Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Yumanity Therapeutics (FRA:8IY) Business Description

Traded in Other Exchanges
N/A
Address
40 Guest Street, Suite 4410, Boston, MA, USA, 02135
Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases. The company's lead program, YTX-7739, is in phase 1 clinical development for Parkinson's disease.

Yumanity Therapeutics (FRA:8IY) Headlines

No Headlines